Dartmouth Health (E.P.Z., S.K.), Lebanon, NH.
Dartmouth Institute, Lebanon, NH (E.P.Z., A.J.O.).
Circulation. 2023 Feb 14;147(7):586-596. doi: 10.1161/CIRCULATIONAHA.122.062765. Epub 2023 Feb 13.
The comparative real-world outcomes of older patients with atrial fibrillation (AF) treated with anticoagulation compared with left atrial appendage occlusion (LAAO) may be different from those in clinical trials because of differences in anticoagulation strategies and patient demographics, including a greater proportion of women. We sought to compare real-world outcomes between older patients with AF treated with anticoagulation and those treated with LAAO by sex.
Using Medicare claims data from 2015 to 2019, we identified LAAO-eligible beneficiaries and divided them into sex subgroups. Patients receiving LAAO were matched 1:1 to those receiving anticoagulation alone through propensity score matching. The risks of mortality, stroke or systemic embolism, and bleeding were compared between matched groups with adjustment for potential confounding characteristics in Cox proportional hazards models.
Among women, 4085 LAAO recipients were matched 1:1 to those receiving anticoagulation; among men, 5378 LAAO recipients were similarly matched. LAAO was associated with a significant reduction in the risk of mortality for women and men (hazard ratio [HR], 0.509 [95% CI, 0.447-0.580]; and HR, 0.541 [95% CI, 0.487-0.601], respectively; <0.0001), with a similar finding for stroke or systemic embolism (HR, 0.655 [95% CI, 0.555-0.772]; and HR, 0.649 [95% CI, 0.552-0.762], respectively; <0.0001). Bleeding risk was significantly greater in LAAO recipients early after implantation but lower after the 6-week periprocedural period for women and men (HR, 0.772 [95% CI, 0.676-0.882]; and HR, 0.881 [95% CI, 0.784-0.989], respectively; <0.05).
In a real-world population of older Medicare beneficiaries with AF, compared with anticoagulation, LAAO was associated with a reduction in the risk of death, stroke, and long-term bleeding among women and men. These findings should be incorporated into shared decision-making with patients considering strategies for reduction in AF-related stroke.
与临床试验相比,接受抗凝治疗的老年房颤(AF)患者与接受左心耳封堵(LAAO)治疗的患者的真实世界结局可能有所不同,这可能是由于抗凝策略和患者人群的差异所致,包括女性比例更高。我们旨在比较女性和男性接受抗凝治疗和 LAAO 治疗的老年 AF 患者的真实世界结局。
我们使用 2015 年至 2019 年的医疗保险索赔数据,确定了符合 LAAO 条件的受益人和按性别划分的亚组。通过倾向评分匹配,将接受 LAAO 的患者与单独接受抗凝治疗的患者进行 1:1 匹配。在 Cox 比例风险模型中,通过调整潜在混杂特征,比较匹配组之间的死亡率、卒中和全身性栓塞以及出血风险。
在女性中,4085 名 LAAO 接受者与接受抗凝治疗的患者进行了 1:1 匹配;在男性中,5378 名 LAAO 接受者也进行了类似的匹配。对于女性和男性,LAAO 与死亡率风险降低显著相关(风险比 [HR],0.509 [95%置信区间,0.447-0.580];和 HR,0.541 [95%置信区间,0.487-0.601];均<0.0001),卒中和全身性栓塞风险也有类似的发现(HR,0.655 [95%置信区间,0.555-0.772];和 HR,0.649 [95%置信区间,0.552-0.762];均<0.0001)。女性和男性 LAAO 接受者在植入后早期出血风险显著增加,但在 6 周围手术期后出血风险降低(HR,0.772 [95%置信区间,0.676-0.882];和 HR,0.881 [95%置信区间,0.784-0.989];均<0.05)。
在一项真实世界的老年医疗保险受益人群中,与抗凝治疗相比,LAAO 可降低女性和男性房颤患者的死亡、卒中和长期出血风险。这些发现应该纳入考虑降低房颤相关卒中风险的患者决策中。